Latest Breaking News On - Alberto gabizon - Page 1 : comparemela.com
Old West: “Investment in Rafael Holdings (RFL) Represents an Extremely Asymmetric Opportunity”
Old West Investment Management, an investment management firm, published its first quarter 2021 investor letter – a copy of which can be downloaded here. An average return of 25% was delivered by the fund for the Q1 of 2021, ahead of its S&P 500 benchmark that delivered a 6% return for the same period. You can view the fund’s top 5 holdings to have a peek at their top bets for 2021.
Old West Investment Management, in their Q1 2021 investor letter, mentioned Rafael Holdings, Inc. (NYSE: RFL), and shared their insights on the company. Rafael Holdings, Inc. is a Newark, New Jersey-based clinical-stage oncology pharmaceutical company that currently has a $682.7 million market capitalization. Since the beginning of the year, RFL delivered an impressive 76.72% return, extending its 12-month gains to 192.06%. As of April 28, 2021, the stock closed at $41.38 per share.
Taiwan
Japan
South-korea
Howard-jonas
Sanjeev-luther
Alberto-gabizon
Kalinovskiy-shutterstock
Sol-barer
Chi-van-dang
Rafael-pharma
Richard-axel
Rafael-pharmaceuticals
ForDoz Enters Contract Manufacturing Agreement for Oncology Liposomal Product with LipoMedix
News provided by
Share this article
Share this article
EAST WINDSOR, N.J., Feb. 19, 2021 /PRNewswire/ ForDoz Pharma has entered into an agreement with LipoMedix for manufacturing its lead compound, pegylated liposomal Promitil
® (PL-MLP) for a Phase 2 clinical study.
Promitil s unique liposomal formulation is designed for selective delivery of the therapeutic agent to cancer-affected tissues and is ideally suited for cancer chemoradiotherapy. In studies, it has been shown to be active against a broad variety of cancer types in animal models, including colorectal, gastric, pancreatic and multi-drug resistant tumors.
Jerusalem
Israel-general
Israel
United-states
New-jersey
Hebrew-university
Yerushalayim
Fordoz-pharma
Alberto-gabizon
Sanjeev-luther
Prnewswire-fordoz-pharma
Linkedin